Other BH3 mimetics targeting MCL-1 and BCL-XL are also in various stages of preclinical and clinical development and have been shown to have activity in a myriad of cancer types including highly chemoresistant solid tumors [56, 57]. Here, BCL2L1 is linked to cancer.